Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Merkel Cell CarcinomaAdvanced or Metastatic Cutaneous Squamous Cell CarcinomaAdvanced or Metastatic MelanomaAdvanced or Metastatic Head and Neck Squamous Cell CarcinomaAdvanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Exicure, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT03684785
- Locations
- 🇺🇸
John Wayne Cancer Institute / Providence St. John's Health Center, Santa Monica, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Medical Center / Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of AST-008 in Healthy Subjects
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Exicure, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03086278
- Locations
- 🇬🇧
Richmond Pharmacology, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath